Favipiravir showing excellent clinical results in China

▴ zhejiang-hisun-pharmaceutical-favipiravir-brought-pandemic-under-control
Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir

COVID-19 has become a global pandemic. China's successful control of the pandemic has set a good example for other countries. Many have followed China to take effective measures like enforcing lockdowns and wearing masks have all been proved to be effective. As part of China's constantly validated treatment approaches, Favipiravir is also the epitome of its response to the virus.

Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a range of RNA viruses, including Ebola, influenza and COVID-19. No evident adverse reactions have been found since it came into the market. Unlike traditional antiviral drugs, Favipiravir can directly prevent the virus from replicating itself in cells, with a mechanism of action similar to Remdesivir.

Originally developed by Toyama Chemical Co., Ltd., Favipiravir was approved as a strategic stockpile in Japan. In 2016, the patent of Favipiravir was exclusively franchised to Zhejiang Hisun Pharmaceutical Co., Ltd. (HISUN), which cooperated with CMAM to develop and launch Favipiravir tablets to the Chinese market in February 2020. Data from clinical tests of Favipiravir published by the Ministry of Science and Technology at a COVID-19 themed press conference on March 17th indicates Favipiravir has shown good clinical efficacy against the disease. It was included in the Major Anti-pandemic Materials by China's State Council, and the Chinese government has unified the allocation of Favipiravir supplies. The medication has also been used to support over 30 countries and achieved good results. All Favipiravir tablets in China are manufactured by HISUN, who recently was honoured as the "Ordnance Factory" responding to the COVID-19 crisis.

Clinical data from the ongoing global multicenter trials shows Favipiravir can clear the virus fast and alleviate the pneumonia symptom of COVID-19 patients with high tolerance and few adverse reactions.

The No.3 People's Hospital of Shenzhen's Favipiravir versus Kaletra trial findings showed: regarding recovery from fever in 2 days, 72.41% in the Favipiravir group versus 26.30% in the Kaletra group; regarding time for patients turning negative in viral nucleic acid tests, 4 days versus 11 days; regarding improvement rate in chest imaging, 91.43% versus 62.22%; regarding adverse reaction rate, 11.43% versus 55.56%.

Zhongnan Hospital of Wuhan University's clinical test using Arbidol as a control group found ordinary Favipiravir-treated patients had a higher clinical recovery rate at the end of the treatment (71.43%), compared with 55.86% in the control group. The auxiliary oxygen therapy or noninvasive mechanical ventilation rate was 8.16% in the Favipiravir group and 17.12% in the Arbidol group. Coughing symptoms improved within 4.57 days, 1.41 days shorter than Arbidol-treated patients.

Tags : #ZhejiangHisunPharma #Remdesivir #GlobalPandemic #China #WuhanUniversity

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Managing High Blood Pressure: Importance for Kidney HealthMarch 15, 2025
Teenagers Are Losing Friends While Chasing Perfection: Here’s WhyMarch 13, 2025
Your Desk Job is Destroying Your Mind: Here’s How to Fight BackMarch 13, 2025
Wow! Momo Disrupts FMCG Cup Noodles Market with 'Desi-Asian Flavours' – A First in IndiaMarch 13, 2025
How India’s Kidney Health Crisis is Growing UnnoticedMarch 13, 2025
Stuck Between the Snooze Button and the Hustle: Entrepreneurs Struggle to Get Quality SleepMarch 13, 2025
Can Coffee Keep You Steady on Your Feet? New Study Reveals the TruthMarch 13, 2025
NephroPlus Sets Guinness World Record & India Book of Records Title for Largest Kidney Health Screening DriveMarch 12, 2025
India Choosing to Eat Healthy; Order Volumes Up by 60% for Nutritional ProductsMarch 12, 2025
Amrita students win first prize at DecodeX 2025 hackathonMarch 12, 2025
Why Millions Are Losing Their Sight to Glaucoma And How You Can Prevent ItMarch 12, 2025
Çelebi India Ranks 3rd Worldwide in Ground Handling Performance for Turkish CargoMarch 12, 2025
Advancing Road Safety Through Clear Vision: VARS 4.0 Sets Bold AgendaMarch 12, 2025
The Deadly Cost of the “Perfect Body”: When Diet Trends Turn FatalMarch 12, 2025
Lighthouse Canton’s LC GenInnov Global Innovation Fund Secures Investment from Kotak Mahindra Asset ManagementMarch 11, 2025
TTK Prestige Revolutionizes Cooking with Innovative AirFlip Two-in-One Air Fryer and GrillMarch 11, 2025
Rewriting Immunology: The Discovery That Could Replace Traditional AntibioticsMarch 11, 2025
Is Your Cooking Oil Poisoning You? The Truth About Seed OilsMarch 11, 2025
Think Before You Bite: How Fatty Foods Can Trigger Brain Damage in Just 3 DaysMarch 11, 2025
Ditch the Pills: The Secret to Beating Insomnia is in Your WorkoutMarch 11, 2025